MicuRx Starts China Phase III Trial of Novel Antibiotic

MicuRx Pharma has started enrolling patients in a pivotal China Phase III trial of MRX-I, its oral antibiotic for complicated skin and skin structure infections (cSSSI). MicuRx, a San Francisco-Shanghai pharma, positions MRX-I as a next-generation oxazolidinone that will treat infections caused by multi-drug resistant gram-positive bacteria. MicuRx expects MRX-I will prove non-inferiority to linezolid with a better side effect profile. The company says cSSSI infections are often drug resistant. More details.... Share this with colleagues: // //